Navigation Links
New Skin Rejuvenation Discovery Receives Commercial Backing
Date:11/4/2008

BOSTON, Nov. 4 /PRNewswire/ -- Allied Minds funds research to reduce wrinkles by developing a natural replacement for artificial dermal fillers. Allied Minds, a seed investment firm specializing in early stage university business ventures, to fund new research with Lawrence Berkeley National Laboratory through creation of start-up company, ProGDerm, Inc. The research led by Doctors Eva Turley and Mina Bissell will develop a technology based on modulation of the RHAMM protein to induce the controlled generation of fat cells to replace those lost in the aging process. While researching the regulation of cell motility as it relates to the spread of cancer, it was discovered that modulating the RHAMM protein increases the deposition of subcutaneous fat while decreasing unhealthy visceral fat. This technique could provide a non-surgical approach to normalizing skin appearance after the aging process has caused wrinkles and folds and after reconstructive surgery.

This technology would replace the now commonly used artificial dermal fillers prescribed to alleviate the appearance of age related wrinkles. Current filler products are injected under the skin to replace volume lost with the decrease of subcutaneous fat that accompanies the aging process. These filler products however, are of short duration, can cause pain and bruising, require multiple treatments, and often result in an unnatural appearance. Modulating RHAMM proteins represents a natural process that has the potential to actually induce controllable re-growth of the patient's own subcutaneous fat in targeted areas to help restore a youthful appearance without artificial dermal fillers.

The ProGDerm product will initially be administered via injection by trained professionals but has the potential to be delivered as a topical cream. The demand for cosmeceuticals - loosely defined as cosmetic products that have medicinal or drug-like benefits - is rapidly increasing particularly within the skin care segment. "There is a vibrant marketplace for the next generation of dermal products. We look forward to entering this exciting new phase with Dr. Turley and Dr. Bissell," says Allied Minds CEO, Chris Silva.

About Allied Minds, Inc.

Allied Minds, Inc. is the premiere seed organization for early-stage technology. We focus on converting academic discoveries into commercial reality by working exclusively with a network of U.S. universities and national labs. By filling the gap between government grants and traditional venture capitalists, Allied Minds focuses on funding innovations with significant transformative potential. Instead of managing funds, we foster early-stage companies through to success, generating value for all stakeholders. We have a nationwide footprint with offices in Boston, Seattle, Washington, D.C. and Los Angeles, and a European presence in London, United Kingdom. For more information, logon to http://www.alliedminds.com.

About Lawrence Berkeley National Lab

Berkeley Lab is a U.S. Department of Energy national laboratory located in Berkeley, California. It conducts unclassified scientific research and is managed by the University of California. Visit the Lab website at http://www.lbl.gov.


'/>"/>
SOURCE Allied Minds, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nutrition 21 Introduces New Product: Iceland Health Skin Rejuvenation(TM)
2. North Carolinas Center For Advanced Medicine & Clinical Research Celebrates Opening of New LKN Medical Spa and Rejuvenation Center
3. New Stretch Mark and Skin Rejuvenation Treatment Introduced to Houston by Dr. Zaniewski-Singh
4. Discovery of sugar sensor in intestine could benefit diabetes
5. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
6. Stem cell research produces a key discovery for Fragile X Syndrome
7. Welch Foundation gives $1.6 million for drug discovery research
8. New discovery leaves blood-doping athletes scratching their heads
9. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
10. New discovery leaves blood-doping athletes scratching their heads
11. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Footwear Foundation, the national charitable foundation serving the footwear industry, has broken all ... representing more than 130 companies across 23 states during the months of April ...
(Date:4/29/2016)... Georgia (PRWEB) , ... April 29, 2016 , ... On ... rural hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB ... Rep. Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton School of ... Grand Prize of the 2016 Wharton Business Plan Competition —as well as ... Award, and the Committee Award for Most ‘Wow Factor,’ making them the first ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
Breaking Medicine Technology: